Mylan (MYL) Receives FDA Approval for Generic Version of Takeda's Actoplus Met
Tweet Send to a FriendGet Alerts MYL Hot Sheet
Down)
Trade MYL Now!
Bloomberg reporting Mylan (NYSE: MYL) has won FDA approval for its generic version of Takeda's actoplus met.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Elan Corp (ELN) Could Be Worth $19 in a Takeout - Jefferies
- Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign
- Moneygram (MGI) Higher on Potential Sale
Create E-mail Alert Related Categories
FDA, Rumors
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
